Efficacy of Dapagliflozin on Recurrence after Catheter Ablation for Atrial Fibrillation: the Statistical Analysis Plan of the DARE-AF Trial
Zhao, Z.; Yang, Z.; Wang, C.; Jiang, C.; Dong, J.-Z.; Ma, C.
Show abstract
BackgroundAtrial fibrillation (AF) recurrence is common in patients after catheter ablation. Previous studies have demonstrated a lower risk of AF recurrence after ablation with the use of sodium-glucose cotransporter 2 inhibitors (SGLT2i) among patients with diabetes or heart failure. However, the effects of SGLT2i in AF patients after catheter ablation without current indications for SGLT2i were uncertain. ObjectiveThis trial aims to evaluate the effect of dapagliflozin on AF burden after ablation in persistent atrial fibrillation (PeAF) patients. Study DesignEfficacy of DApagliflozin on REcurrence after catheter ablation for Atrial Fibrillation (DARE-AF) is a parallel-group, randomized, open-label randomized controlled trial. We aim to enroll 200 patients with de novo atrial fibrillation (AF) undergoing catheter ablation, and patients with class I indications for SGLT2 Inh (diabetes, heart failure, or chronic kidney disease) are excluded. PeAF patients will be randomized in a 1:1 ratio to intervention or control group. Patients in the intervention group will receive dapagliflozin 10mg once daily for three months. The primary outcome is AF burden accessed by 7-day single-lead electrocardiogram patches at three months after ablation. ConclusionsDARE-AF is the first clinical trial, aiming to evaluate the effect of 3-month treatment with dapagliflozin on AF burden after catheter ablation in PeAF patients without current indications.
Matching journals
The top 5 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- Differences in coagulation responses to vascular injury between uninterrupted dabigatran and apixaban - a clinical prospective randomized study 96%
- Procedural Volume and Outcomes with Atrial Fibrillation Ablation: A Report from the NCDR AFib Ablation Registry 95%
- Competing Risks in Patients with Primary Prevention Implantable Cardioverters Defibrillators: Global Electrical Heterogeneity and Clinical Outcomes (GEHCO) Study 94%
Similar papers in this journal
Similar papers in this journal
- Apple Watch and Withings Evaluation of Symptoms, Treatment, and Rhythm in those Undergoing Cardioversion (AWE STRUCk): A Pragmatic Randomized Controlled Trial 96%
- Real-world effects of ACE inhibitors and Angiotensin Receptor Blockers: protocol for an emulation study of the ONTARGET trial using electronic health records 95%
- Outcome Disparities by Insurance Plan and Educational Attainment in Patients with Atrial Fibrillation 94%
Similar papers in this journal
- Predictors and outcomes of Cardiac Dyssynchrony among patients with heart failure attending Benjamin Mkapa Hospital in Dodoma, central Tanzania: A protocol of prospective-longitudinal study 94%
- Sex and racial differences in cardiovascular disease risk in patients with atrial fibrillation 94%
- Applications of Machine Learning in Decision Analysis for Dose Management for Dofetilide 94%
Similar papers in this journal
- Screening for Atrial Fibrillation in Older Adults at Primary Care Visits: the VITAL-AF Randomized Controlled Trial 96%
- Arrhythmia and Survival Outcomes among Black and White Patients with a Primary Prevention Defibrillator 94%
- Electrocardiographic Manifestations of Immune Checkpoint Inhibitor Myocarditis 93%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.